Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer

Gideon M. Blumenthal, Paul A. Bunn, Jamie E. Chaft, Caroline E. McCoach, Edith A. Perez, Giorgio V. Scagliotti, David P. Carbone, Hugo J.W.L. Aerts, Dara L. Aisner, Jonas Bergh, Donald A. Berry, Anthony Jarkowski, Nicholas Botwood, Darren A.E. Cross, Max Diehn, Nicole L. Drezner, Robert C. Doebele, Collin M. Blakely, Wilfried E.E. Eberhardt, Enriqueta FelipLuca Gianni, Steven P. Keller, Patrick J. Leavey, Shakun Malik, Francesco Pignatti, Tatiana M. Prowell, Mary W. Redman, Naiyer A. Rizvi, Rafael Rosell, Valerie Rusch, Dirk de Ruysscher, Lawrence H. Schwartz, Rajeshwari Sridhara, Rolf A. Stahel, Stephen Swisher, Janis M Taube, William D. Travis, Patricia Keegan, Jacinta R. Wiens, Ignacio I. Wistuba, Murry W. Wynes, Fred R. Hirsch, Mark G. Kris

Research output: Contribution to journalReview article

Abstract

This Review Article provides a multi-stakeholder view on the current status of neoadjuvant therapy in lung cancer. Given the success of oncogene-targeted therapy and immunotherapy for patients with advanced lung cancer, there is a renewed interest in studying these agents in earlier disease settings with the opportunity to have an even greater impact on patient outcomes. There are unique opportunities and challenges with the neoadjuvant approach to drug development. To achieve more rapid knowledge turns, study designs, endpoints, and definitions of pathologic response should be standardized and harmonized. Continued dialogue with all stakeholders will be critical to design and test novel induction strategies, which could expedite drug development for patients with early lung cancer who are at high risk for metastatic recurrence.

Original languageEnglish (US)
Pages (from-to)1818-1831
Number of pages14
JournalJournal of Thoracic Oncology
Volume13
Issue number12
DOIs
StatePublished - Dec 1 2018

Fingerprint

Neoadjuvant Therapy
Lung Neoplasms
Oncogenes
Pharmaceutical Preparations
Immunotherapy
Recurrence
Therapeutics

Keywords

  • Induction chemotherapy
  • Neoadjuvant therapy
  • Pathologic response
  • Preoperative therapy
  • Resectable lung cancer

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Blumenthal, G. M., Bunn, P. A., Chaft, J. E., McCoach, C. E., Perez, E. A., Scagliotti, G. V., ... Kris, M. G. (2018). Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. Journal of Thoracic Oncology, 13(12), 1818-1831. https://doi.org/10.1016/j.jtho.2018.09.017

Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. / Blumenthal, Gideon M.; Bunn, Paul A.; Chaft, Jamie E.; McCoach, Caroline E.; Perez, Edith A.; Scagliotti, Giorgio V.; Carbone, David P.; Aerts, Hugo J.W.L.; Aisner, Dara L.; Bergh, Jonas; Berry, Donald A.; Jarkowski, Anthony; Botwood, Nicholas; Cross, Darren A.E.; Diehn, Max; Drezner, Nicole L.; Doebele, Robert C.; Blakely, Collin M.; Eberhardt, Wilfried E.E.; Felip, Enriqueta; Gianni, Luca; Keller, Steven P.; Leavey, Patrick J.; Malik, Shakun; Pignatti, Francesco; Prowell, Tatiana M.; Redman, Mary W.; Rizvi, Naiyer A.; Rosell, Rafael; Rusch, Valerie; de Ruysscher, Dirk; Schwartz, Lawrence H.; Sridhara, Rajeshwari; Stahel, Rolf A.; Swisher, Stephen; Taube, Janis M; Travis, William D.; Keegan, Patricia; Wiens, Jacinta R.; Wistuba, Ignacio I.; Wynes, Murry W.; Hirsch, Fred R.; Kris, Mark G.

In: Journal of Thoracic Oncology, Vol. 13, No. 12, 01.12.2018, p. 1818-1831.

Research output: Contribution to journalReview article

Blumenthal, GM, Bunn, PA, Chaft, JE, McCoach, CE, Perez, EA, Scagliotti, GV, Carbone, DP, Aerts, HJWL, Aisner, DL, Bergh, J, Berry, DA, Jarkowski, A, Botwood, N, Cross, DAE, Diehn, M, Drezner, NL, Doebele, RC, Blakely, CM, Eberhardt, WEE, Felip, E, Gianni, L, Keller, SP, Leavey, PJ, Malik, S, Pignatti, F, Prowell, TM, Redman, MW, Rizvi, NA, Rosell, R, Rusch, V, de Ruysscher, D, Schwartz, LH, Sridhara, R, Stahel, RA, Swisher, S, Taube, JM, Travis, WD, Keegan, P, Wiens, JR, Wistuba, II, Wynes, MW, Hirsch, FR & Kris, MG 2018, 'Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer', Journal of Thoracic Oncology, vol. 13, no. 12, pp. 1818-1831. https://doi.org/10.1016/j.jtho.2018.09.017
Blumenthal GM, Bunn PA, Chaft JE, McCoach CE, Perez EA, Scagliotti GV et al. Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. Journal of Thoracic Oncology. 2018 Dec 1;13(12):1818-1831. https://doi.org/10.1016/j.jtho.2018.09.017
Blumenthal, Gideon M. ; Bunn, Paul A. ; Chaft, Jamie E. ; McCoach, Caroline E. ; Perez, Edith A. ; Scagliotti, Giorgio V. ; Carbone, David P. ; Aerts, Hugo J.W.L. ; Aisner, Dara L. ; Bergh, Jonas ; Berry, Donald A. ; Jarkowski, Anthony ; Botwood, Nicholas ; Cross, Darren A.E. ; Diehn, Max ; Drezner, Nicole L. ; Doebele, Robert C. ; Blakely, Collin M. ; Eberhardt, Wilfried E.E. ; Felip, Enriqueta ; Gianni, Luca ; Keller, Steven P. ; Leavey, Patrick J. ; Malik, Shakun ; Pignatti, Francesco ; Prowell, Tatiana M. ; Redman, Mary W. ; Rizvi, Naiyer A. ; Rosell, Rafael ; Rusch, Valerie ; de Ruysscher, Dirk ; Schwartz, Lawrence H. ; Sridhara, Rajeshwari ; Stahel, Rolf A. ; Swisher, Stephen ; Taube, Janis M ; Travis, William D. ; Keegan, Patricia ; Wiens, Jacinta R. ; Wistuba, Ignacio I. ; Wynes, Murry W. ; Hirsch, Fred R. ; Kris, Mark G. / Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. In: Journal of Thoracic Oncology. 2018 ; Vol. 13, No. 12. pp. 1818-1831.
@article{ad8ecd22179d4566b74b52242832d26c,
title = "Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer",
abstract = "This Review Article provides a multi-stakeholder view on the current status of neoadjuvant therapy in lung cancer. Given the success of oncogene-targeted therapy and immunotherapy for patients with advanced lung cancer, there is a renewed interest in studying these agents in earlier disease settings with the opportunity to have an even greater impact on patient outcomes. There are unique opportunities and challenges with the neoadjuvant approach to drug development. To achieve more rapid knowledge turns, study designs, endpoints, and definitions of pathologic response should be standardized and harmonized. Continued dialogue with all stakeholders will be critical to design and test novel induction strategies, which could expedite drug development for patients with early lung cancer who are at high risk for metastatic recurrence.",
keywords = "Induction chemotherapy, Neoadjuvant therapy, Pathologic response, Preoperative therapy, Resectable lung cancer",
author = "Blumenthal, {Gideon M.} and Bunn, {Paul A.} and Chaft, {Jamie E.} and McCoach, {Caroline E.} and Perez, {Edith A.} and Scagliotti, {Giorgio V.} and Carbone, {David P.} and Aerts, {Hugo J.W.L.} and Aisner, {Dara L.} and Jonas Bergh and Berry, {Donald A.} and Anthony Jarkowski and Nicholas Botwood and Cross, {Darren A.E.} and Max Diehn and Drezner, {Nicole L.} and Doebele, {Robert C.} and Blakely, {Collin M.} and Eberhardt, {Wilfried E.E.} and Enriqueta Felip and Luca Gianni and Keller, {Steven P.} and Leavey, {Patrick J.} and Shakun Malik and Francesco Pignatti and Prowell, {Tatiana M.} and Redman, {Mary W.} and Rizvi, {Naiyer A.} and Rafael Rosell and Valerie Rusch and {de Ruysscher}, Dirk and Schwartz, {Lawrence H.} and Rajeshwari Sridhara and Stahel, {Rolf A.} and Stephen Swisher and Taube, {Janis M} and Travis, {William D.} and Patricia Keegan and Wiens, {Jacinta R.} and Wistuba, {Ignacio I.} and Wynes, {Murry W.} and Hirsch, {Fred R.} and Kris, {Mark G.}",
year = "2018",
month = "12",
day = "1",
doi = "10.1016/j.jtho.2018.09.017",
language = "English (US)",
volume = "13",
pages = "1818--1831",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "12",

}

TY - JOUR

T1 - Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer

AU - Blumenthal, Gideon M.

AU - Bunn, Paul A.

AU - Chaft, Jamie E.

AU - McCoach, Caroline E.

AU - Perez, Edith A.

AU - Scagliotti, Giorgio V.

AU - Carbone, David P.

AU - Aerts, Hugo J.W.L.

AU - Aisner, Dara L.

AU - Bergh, Jonas

AU - Berry, Donald A.

AU - Jarkowski, Anthony

AU - Botwood, Nicholas

AU - Cross, Darren A.E.

AU - Diehn, Max

AU - Drezner, Nicole L.

AU - Doebele, Robert C.

AU - Blakely, Collin M.

AU - Eberhardt, Wilfried E.E.

AU - Felip, Enriqueta

AU - Gianni, Luca

AU - Keller, Steven P.

AU - Leavey, Patrick J.

AU - Malik, Shakun

AU - Pignatti, Francesco

AU - Prowell, Tatiana M.

AU - Redman, Mary W.

AU - Rizvi, Naiyer A.

AU - Rosell, Rafael

AU - Rusch, Valerie

AU - de Ruysscher, Dirk

AU - Schwartz, Lawrence H.

AU - Sridhara, Rajeshwari

AU - Stahel, Rolf A.

AU - Swisher, Stephen

AU - Taube, Janis M

AU - Travis, William D.

AU - Keegan, Patricia

AU - Wiens, Jacinta R.

AU - Wistuba, Ignacio I.

AU - Wynes, Murry W.

AU - Hirsch, Fred R.

AU - Kris, Mark G.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - This Review Article provides a multi-stakeholder view on the current status of neoadjuvant therapy in lung cancer. Given the success of oncogene-targeted therapy and immunotherapy for patients with advanced lung cancer, there is a renewed interest in studying these agents in earlier disease settings with the opportunity to have an even greater impact on patient outcomes. There are unique opportunities and challenges with the neoadjuvant approach to drug development. To achieve more rapid knowledge turns, study designs, endpoints, and definitions of pathologic response should be standardized and harmonized. Continued dialogue with all stakeholders will be critical to design and test novel induction strategies, which could expedite drug development for patients with early lung cancer who are at high risk for metastatic recurrence.

AB - This Review Article provides a multi-stakeholder view on the current status of neoadjuvant therapy in lung cancer. Given the success of oncogene-targeted therapy and immunotherapy for patients with advanced lung cancer, there is a renewed interest in studying these agents in earlier disease settings with the opportunity to have an even greater impact on patient outcomes. There are unique opportunities and challenges with the neoadjuvant approach to drug development. To achieve more rapid knowledge turns, study designs, endpoints, and definitions of pathologic response should be standardized and harmonized. Continued dialogue with all stakeholders will be critical to design and test novel induction strategies, which could expedite drug development for patients with early lung cancer who are at high risk for metastatic recurrence.

KW - Induction chemotherapy

KW - Neoadjuvant therapy

KW - Pathologic response

KW - Preoperative therapy

KW - Resectable lung cancer

UR - http://www.scopus.com/inward/record.url?scp=85056748537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056748537&partnerID=8YFLogxK

U2 - 10.1016/j.jtho.2018.09.017

DO - 10.1016/j.jtho.2018.09.017

M3 - Review article

C2 - 30268698

AN - SCOPUS:85056748537

VL - 13

SP - 1818

EP - 1831

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 12

ER -